Bracing for 22.9%: What the 2025 VPAG Payback Rate Means

The 2025 headline payment percentage for eligible sales of newer medicines under the UK Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has been set at 22.9%.

For manufacturers, a figure of this size is not simply a finance-line adjustment. It affects net revenue, forecasting, launch assumptions and the way the UK is positioned within global pricing strategy.

Why 22.9% matters

VPAG is intended to balance several objectives: supporting patient access, maintaining a financially sustainable NHS and encouraging a competitive UK life-sciences environment. The payment mechanism limits the growth of qualifying branded-medicine spend by requiring participating companies to make payments on eligible sales.

At 22.9%, the 2025 headline rate for newer medicines is material enough to change the economics of a launch. A list price that appears attractive in a conventional gross-revenue forecast can look very different once the scheme payment is incorporated.

Gross price is not net revenue

The rate reinforces an important principle for global pricing teams: UK public prices should not be interpreted as a simple proxy for realised revenue. VPAG, commercial agreements and other deductions can create a substantial difference between the published price and the net economics of the market.

That distinction matters in International Reference Pricing. External markets may reference a visible UK list price even though the manufacturer’s realised UK revenue is materially lower. In effect, the UK can provide a relatively high reference point externally while delivering a significantly lower net price internally.

Forecasting and portfolio implications

Companies should incorporate VPAG explicitly into scenario models rather than applying it as an afterthought. The impact will differ by portfolio mix, medicine age, growth expectations and the interaction with individual commercial arrangements.

For launches, teams should test whether the UK remains economically attractive under different demand scenarios and whether a change in UK timing would alter wider IRP exposure. For established products, the focus may be on forecast accuracy, budget planning and understanding how scheme payments interact with lifecycle strategy.

Keep the UK decision in global context

A high payment percentage can create pressure to view the UK purely through a local profitability lens. That would be incomplete. The market’s strategic value can also include early access, evidence generation, a globally visible price and its role within international reference baskets.

The right decision therefore depends on the combined local and global economics. As VPAG evolves, integrated gross-to-net and IRP modelling will be essential to understand that full picture.

This article reflects the market and policy context at the date of publication.

Further reading

• UK Government — VPAG payment percentage for 2025